Three independent measurements of 60 s duration were performed at 25 C. connections. Then, we characterized the in-solution conversation via co-incubation, ultracentrifugation, and analysis of the pelleted proteins. This showed virtually irreversible binding up to an at least 10:1 Tz/vault-Z ratio. As a proof of concept, we labeled the Fc portion of Tz with a fluorophore and conjugated it with the nanoparticle, along with either Tz or Cetuximab, another monoclonal Zalcitabine antibody. Thus, we could demonstrate antibody-dependent, selective uptake by the SKBR3 and MDA-MB 231 breast malignancy cell lines. These investigations provide a novel, flexible technological platform that significantly extends vault-Zs applications, in that it can be stably conjugated with finely adjusted amounts of antibodies as well as of other molecules, such as fluorophores, cell-targeting peptides, or drugs, using the Fc portion as a scaffold. Keywords: vault nanoparticle, major vault protein, expression system, antibody-mediated targeting, Fc antibody portion, surface plasmon resonance, liquid chromatography/mass spectrometry 1. Introduction Recent years have witnessed a growing impact of nanotechnology in biomedicine due to the amazing therapeutic and diagnostic potential of nanoparticles (NPs; for considerable reviews, observe [1,2]). NPs are frequently employed for malignancy treatment, being loaded for this Zalcitabine purpose Rabbit Polyclonal to HSP105 with specific anticancer drugs [3,4] and equipped with monoclonal antibodies (MoAbs), proteins, or peptides that selectively direct them to malignancy cells [1,5,6,7]. MoAbs are capable of binding molecular receptors overexpressed at the malignancy cell surface, which ensures a targeted delivery and endocytic uptake of the therapeutic agent [8]. Several methods for NP functionalization have been developed, including passive adsorption, covalent binding based on different protocols, including carbodiimide, maleimide, or click chemistry, or binding via adapter molecules. However, these methods often suffer from major disadvantages in that they are complex Zalcitabine and time-consuming, and/or do not necessarily guarantee the correct orientation required for MoAb to effectively bind to the target molecule [7]. With regard to the nature of nano-sized materials available to date, there is a wide and diversified repertoire encompassing several varieties of NPs, including inorganic, polymeric, lipidic, and protein-based nanomaterials [1,2]. In particular, in the last decade, the latter have gained growing interest as drug delivery systems, due to the several advantages they offer, especially in terms of a lack of toxicity and low immunogenicity, biodegradability, biocompatibility, size homogeneity, and colloidal stability. In this context, the vault NP stands out for its unique properties. Vaults are natural ribonucleoproteins found in several eukaryotes [9,10]. In their molecular assembly, the 99 kDa major vault protein (MVP) is present in 78 copies and generates a barrel-like, roughly ovoidal natural NP consisting of two symmetrical halves, whose C-termini form two protruding caps at both ends [11,12]. Vaults also enclose other molecular Zalcitabine components, i.e., the 193 kDa vault poly(ADP-ribose) polymerase, the 290 kDa telomerase-associated protein-1 (TEP1), and one or more small untranslated RNAs [13,14,15,16,17]. Overall, the molecular mass of vault particles amounts to about 13 MDa, their size is usually 72.5 nm 41 nm 41 nm, and the internal cavity volume is 5 104 nm3. Notably, a well-assembled vault structure can be produced by expressing the sole MVP, as originally shown in insect cells [18,19]. Even though physiological functions of this nanocomplex are only partially comprehended, numerous reports spotlight Zalcitabine its involvement in several pro-survival functions [10,20]. Thanks to the aforementioned characteristics, this macromolecular assembly has attracted growing attention as a tool for drug/gene delivery, often directed to malignancy cells [21]. Actually, it was shown that the sole MVP can assemble into an empty vault, which not only can accommodate large amounts of cargo molecules but can also be targeted to specific cell surface receptors, provided it is bound to a targeting molecule (e.g., MoAbs) via genetic [22] or chemical methods [23]. Of amazing interest, in this respect, is the development of a vault variant transporting, at the MVP C-terminus, a staphylococcal, protein A-derived sequence, referred to as Z.
